Axogen, Inc. (AXGN)
AXGNNASDAQ-CMBiotechnology: Electromedical & Electrotherapeutic Apparatus
$50.51
-0.1350 (-0.27%) today
Regular session, Nov 10, 2:56 PM ET
- Market cap
- $3.02bn
- P/E
- –
- EPS, last 4 quarters
- $-0.3200
- Dividend yield
- –
- Day range
- $49.23 to $50.90
- 52-week range
- $23.00 to $52.91
- Average volume
- 1.57m
- Previous close
- $50.64
Analysts
11 coveringBuy11 buy, 0 hold, 0 sell
Targets a year out average $58.00, +14.8% from here
Earnings
next estimate $-0.0100Next report
Dec 2025
-2700.0%
Mar 2026
+82.1%
Jun 2026
+25.0%
Sep 2026
+233.3%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $59.90m | $61.46m | $69.73m | $75.83m |
| Gross profit | $44.41m | $46.19m | $50.67m | $56.73m |
| Operating income | -$9.77m | -$2.83m | -$2.16m | $955.0k |
| Net income | -$13.16m | -$19.58m | -$1.52m | $2.33m |
Last four quarters: revenue $266.93m, margin -12.0%, free cash flow $22.04m
News
8 latest- Axogen, Inc. Announces Decision to Move Forward with Prostate Market Launch and Highlights $754m TAMFintel · 23 hours ago
- Axogen Consensus Price Target Raised 10.66% to $60.27Fintel · Nov 2, 2026
- GMED vs. AXGN: Which Stock Should Value Investors Buy Now?Zacks · Nov 2, 2026
- Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year?Zacks · Oct 29, 2026
- AxoGen Q3 Earnings Call HighlightsMarketBeat · Oct 28, 2026
- Noteworthy Wednesday Option Activity: SPCX, AXGN, GFLBNK Invest · Oct 28, 2026
- Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30% RTTNews · Oct 28, 2026
- Axogen (AXGN) Q3 2026 Earnings Call TranscriptThe Motley Fool · Oct 28, 2026
The company
Axogen (Nasdaq: AXGN) is focused on the science, development and commercialization of technologies for peripheral nerve repair. With a mission to make nerve repair the expected standard of care, Axogen advances the field through research, education, and collaboration with surgeons and healthcare providers across a global network. Axogen's product portfolio includes Avance (acellular nerve allograft-arwx), Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, Avive+ Soft Tissue Matrix, and NerveTape.
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- axogeninc.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.